News

Besides specialty pharmaceutical pricing, the cost of compounded drugs is highlighted

Company wins $10 million in venture capital as it lines up key life sciences service providers

Literature survey from Altarum Institute finds a growing body of evidence of value

IHS, hereafter to be known as ARxIUM, will expand its injectable-compounding business to include oral solids

Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions

A family-owned pharmaceutical manufacturer plots a 21st-century growth plan

AmerisourceBergen-Walgreens Alliance Boots, and H. D. Smith-Legisym are runners-up

Company uses online media to promote fill rates by more than 50%

Identity Hub expedites access to regulated content in prescribing and other commercial applications

Collaboration with American College of Cardiology could result in new health-outcomes results

$2-billion acquisition brings a $5-billion/yr PBM to Rite Aid's 4,600 retail stores

Association's annual specialty-distribution study focuses trend in oncology, chronic diseases

The Parenteral Drug Association offers risk management guidance*

2015 spring meeting focuses on meeting transportation bottlenecks

1.5-10% improvement in 'revenue capture' is possible

Reporting by pharma companies on spending on physicians is becoming a non-event

Analysis from Prime Therapeutics points to severe cost hurdles for biosimilars developed and marketed in the US

New design from Emball'Iso triples payload capacity

It's still early days in making medical marijuana--and cannabis-based pharmaceuticals--part of normal dispensing

Unifying the management of clinical research documentation and marketing content saves time and accelerates speed-to-therapy

GDP standards drive higher performance standards for packaging

Manufacturers will need to refine their interactions with healthcare providers and produce better outcomes research and adherence programs to compete

Pharmaceutical Commerce's annual Cold Chain Sourcebook projects 44% growth over the 2013-2019 span

'Filgrastim-sndz' is Sandoz' Zarxio, the biosimilar of Amgen's Neuprogen

Success in managing DSCSA traceability requirements bring a $20-million equity investment

Reporting by pharma companies on spending on physicians is becoming a non-event